A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

BACKGROUND: To evaluate the efficacy of cetuximab combined with modified FOLFIRI (mFOLFIRI) as a second-line treatment in metastatic gastric cancer patients and to identify potential biomarkers of clinical outcomes. METHODS: All 61 patients received an initial intravenous (IV) dose of cetuximab (400...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Liu, Xin, Guo, Weijian, Zhang, Wen, Yin, Jiliang, Zhang, Jun, Zhu, Xiaodong, Liu, Tianshu, Chen, Zhiyu, Wang, Biyun, Chang, Jianhua, Lv, Fangfang, Hong, Xiaonan, Wang, Huijie, Wang, Jialei, Zhao, Xinmin, Wu, Xianghua, Li, Jin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5348753/
https://ncbi.nlm.nih.gov/pubmed/28288572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3174-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados